HomeTWST • NASDAQ
add
Twist Bioscience Corp
Previous close
$43.20
Day range
$41.51 - $43.86
Year range
$11.81 - $44.92
Market cap
2.47B USD
Avg Volume
1.11M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
(USD) | Mar 2024info | Y/Y change |
---|---|---|
Revenue | 75.30M | 25.13% |
Operating expense | 79.77M | -1.93% |
Net income | -45.49M | 23.10% |
Net profit margin | -60.41 | 38.55% |
Earnings per share | -0.79 | 25.66% |
EBITDA | -40.58M | 27.27% |
Effective tax rate | -0.76% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Mar 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 293.34M | -24.33% |
Total assets | 702.85M | -17.69% |
Total liabilities | 142.72M | -4.85% |
Total equity | 560.13M | — |
Shares outstanding | 58.23M | — |
Price to book | 4.49 | — |
Return on assets | -17.03% | — |
Return on capital | -18.36% | — |
Cash Flow
Net change in cash
(USD) | Mar 2024info | Y/Y change |
---|---|---|
Net income | -45.49M | 23.10% |
Cash from operations | -19.42M | 56.14% |
Cash from investing | -5.24M | -112.73% |
Cash from financing | 1.83M | 19.87% |
Net change in cash | -22.90M | -1,396.73% |
Free cash flow | -6.02M | 85.09% |
About
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
The company was represented by Leproust at a March 2021 tabletop exercise at the Munich Security Conference simulating an outbreak of weaponized monkeypox.
In May 2021, Twist Bioscience and Genome Project-Write launched a new CAD platform for whole genome design. The CAD will automate workflows to enable collaborative efforts critical for scale-up from designing plasmids to megabases across entire genomes. Wikipedia
Founded
2013
Website
Employees
919